Condition

ALK Gene Translocation

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 2 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common interventions5

Lead sponsors shown2

Clinical trials

2 shown

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung CancerNCT02846792 · 2017-06-14

TERMINATED

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)NCT02201992 · 2015-03-23

ACTIVE_NOT_RECRUITING

Common interventions

Clinical ObservationOTHER1 CrizotinibDRUG1 Laboratory Biomarker AnalysisOTHER1 NivolumabBIOLOGICAL1 PlinabulinDRUG1

Leading sponsors

ECOG-ACRIN Cancer Research Group 1 University of Washington 1

Trial status mix

ACTIVE_NOT_RECRUITING1

TERMINATED1

Phase mix

PHASE11

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.